Hematologist. Treat and study thrombosis and hemostasis in cancer patients. Passionate #Arsenal⚽️supporter & 🧘🏼♂️.
Israel
- Tweets 96
- Following 127
- Followers 201
- Likes 244
Avi Leader retweeted
Simple intervention that makes sense! STRATUS #RCT trial led by Dr @DebSiegal and @PHRIresearch in @JAMA_current reported that using small-volume tubes for 🩸 collection⬇️ RBC transfusion in ICU patients. ↔️ in insufficient specimens.
jamanetwork.com/journals/jam…
1
11
40
3,272
Avi Leader retweeted
VTE patients with brain cancer have an increased risk for intracranial bleeding during anticoagulation
Another study by the #RIETEregistry team, leaded by Cecilia Becattini and Michela Giustozzi
20
49
4,173
Avi Leader retweeted
New 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria are out!
Patients need at least 3 points each from the clinical and lab domains (See below) to be classified as having APS. This will be very useful to clinicians :)
acrjournals.onlinelibrary.wi…
@isth
1
55
113
17,820
Avi Leader retweeted
#Match2024 & #FellowMatch
@MSKCancerCenter @MSK_DeptOfMed @TheNRMP @HemOncFellows
I am happy to announce the MSKCC Hematology Focused Fellowship track!
mskcc.org/hcp-education-trai…
17
71
15,739
Avi Leader retweeted
@LeaderAvi presents results from the ABC registry for AC with DOAC or LMWH in brain tumors.
- 🚫diff in rate of spontaneous (not caused by surgery) ICH between DOAC vs LMWH (but numerically ⬇️ with DOAC)
#ISTH2023
4
5
496
Avi Leader retweeted
What is the risk of ICH in patients using DOAC vs LMWH with primary or metastatic brain tumor? @LeaderAvi presents the ABC study at #ISTH2023
1
3
19
2,579
Avi Leader retweeted
🚨Great guidance paper from @AnnaFalanga19 & @LeaderAvi et al. to help with management of these challenging situations.
pubmed.ncbi.nlm.nih.gov/3592…
10
23
4,802
Avi Leader retweeted
LIVE NOW: @LeaderAvi #ISTH2023 SOA Address: Arterial thrombosis is ↑ in cancer & under-treated. Challenges in treatment include ↑ bleeding, drug-drug interactions & ↓ platelets. Cancer-specific #thrombosis management shown ⬇️ in #CoagCapsule. isth.org/23Capsules
7
21
1,801
Avi Leader retweeted
Pts with cancer are at ⬆️ risk of ATE including IS 🧠
Cancer is a known cause of ESUS.
Tx of ESUS in cancer is not well defined.
Pts with cancer and ESUS have a ⬆️ risk of recurrent stroke with DOACs or ASA
Future RCTs are needed (and planned) to guide tx
@LeaderAvi #ISTH2023
1
6
19
1,677
Avi Leader retweeted
Dr. @LeaderAvi providing a great overview of arterial thromboembolism (ATE) in patients with cancer. ATE are often neglected in CAT literature. ATE is common in new diagnosed patient and associates with higher mortality!
#ISTH2023
1
9
29
1,443
Avi Leader retweeted
A Fib is common in patient with cancer. These patients are at higher risk if ATE but also at high risk of bleeding is also high. Good guidance are available to help clinicians #ISTH2023
@LeaderAvi
1
9
26
2,565
Avi Leader retweeted
Dr. @LeaderAvi presented the second phase of the ABC study which reported on the 65 patients with ICH on anticoagulation during the study. Majority of ICH are overt and intramural. VTE is frequent after ICH. No clear association between AC management and VTE post-ICH.
#ISTH2023
2
10
517
Avi Leader retweeted
Severity of ICH was similar for patients on DOACs and LMWH @LeaderAvi #ISTH2023
5
12
776
Avi Leader retweeted
📣Publication alert: finally published in @TheLancet , the ALIFE2 trial. So thankful to all women who participated and all colleagues who joined the study. LMWH does NOT improve live birth in women with #thrombophilia and #recurrent miscarriage.
thelancet.com/pb-assets/Lanc…
18
114
274
55,701
Avi Leader retweeted
Patients with cancer-associated #thrombosis and #thrombocytopenia have high risks of recurrent VTE and major bleeding. Future RCTs such as the START trial (NCT05255003) are needed!
authors.elsevier.com/c/1h4w5… in @ThrombosisRese1
@MarcCarrier1 @DellucAurelien
16
52
5,371
Now available:
Podcast🎧🗣️ jacc.org/do/10.1016/podcast-…
Editorial 📄 jacc.org/doi/10.1016/j.jacca…
Pop-based cohort of atrial fib/flutter pts with CHA2DS2-VASc score 0-2 not receiving anticoagulation. Newly-diagnosed cancer associated with 2.7-fold ⬆️ in 12-month ATE risk (vs. no cancer). @JACCJournals sciencedirect.com/science/ar… #cvCoag #AFib #CardioOnc
2
209
Avi Leader retweeted
If cerebral vein thrombosis (#CVT) fails to recanalise after 3-6 months, the risk of CVT recurrence is 8.8x higher. Suggests that anticoagulation length should vary depending on recanalisation status. Free PDF in @RPTHjournal.
tinyurl.com/hzk2f864
3
19
39
4,700
Avi Leader retweeted
Now in a large population-based cohort - pts w/ ALK+ #lungcancer at a significantly higher risk for #VTE vs nonALK #nsclc. Awareness is 🗝️! do we need +data or start using prphl💊?
academic.oup.com/oncolo/adva…
2
9
21
1,557
Avi Leader retweeted
📢Alert! Women with #superficial vein #thrombosis (SVT) in #pregnancy had a 10.4% risk of having #VTE in that same pregnancy or postpartum period. That is a huge risk justifying treatment of #SVT. @TheLancetHaem Free download until May 13, 2023 authors.elsevier.com/c/1goj-…
2
65
118
28,199
Avi Leader retweeted
Most venous #thrombosis #VTE pts ▶️treated +DOACs 💊 In new #JTHiC case-based discussion for DOAC interruption perioperatively in pts receiving VTE anticoagulation. #JTHiC @connors_md @jlberrymd @rushadpatell @jzbos @BIDMC_HOFellows
@MSKcancercenter
bit.ly/3Y5dpID
5
11
2,260